V1RE4 Inhibitors
V1RE4 inhibitors are a class of chemical compounds that have been identified for their ability to interact with a specific biological target, referred to as V1RE4, which is typically a protein or receptor involved in certain biochemical pathways. These inhibitors are designed to bind to the V1RE4 site with high specificity, which results in the modulation of the protein's function or the signaling pathways in which the protein is involved. The design and development of V1RE4 inhibitors incorporate advanced techniques in medicinal chemistry and molecular biology to ensure that these compounds exhibit high affinity and selectivity for their target, alongside favorable pharmacokinetic and pharmacodynamic profiles.
The development of V1RE4 inhibitors is grounded in a comprehensive understanding of the structure and function of the V1RE4 protein, which includes knowledge of the three-dimensional structure obtained through techniques such as X-ray crystallography or NMR spectroscopy. Researchers utilize this structural information to identify key binding sites and to design inhibitors that can effectively interact with the protein. Structure-activity relationship (SAR) studies are commonly conducted to optimize the interactions between the inhibitor and the target protein. These studies involve the systematic modification of the inhibitor's chemical structure to improve its binding characteristics and to minimize off-target interactions. The chemical synthesis of V1RE4 inhibitors often requires meticulous planning and execution, as these molecules can feature complex structures with multiple chiral centers, heterocycles, and functional groups that are essential for their inhibitory activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. PI3K signaling is crucial for a variety of cellular functions. Inhibition of PI3K can lead to reduced activity of downstream effectors including AKT, which may indirectly decrease the functional activity of V1RE4 if V1RE4 is functionally downstream of AKT signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, it interferes with the mTORC1 and mTORC2 complexes' signaling pathways, which are implicated in cell growth, proliferation, and survival. If V1RE4 is involved in these processes or downstream of them, rapamycin would decrease its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3Ks, blocking the PI3K/AKT pathway. This inhibition can reduce the phosphorylation and activation of proteins that are regulated by this pathway, potentially affecting the activity of V1RE4 if it is regulated through this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK1/2, which are upstream of ERK1/2 in the MAPK/ERK pathway. By inhibiting MEK, PD98059 can prevent the activation of ERK, thus potentially attenuating the signaling cascade that may control the expression or activity of V1RE4. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. The p38 MAPK pathway is involved in inflammatory responses and stress. Inhibition by SB203580 could lead to decreased activation of transcription factors that regulate V1RE4 expression if V1RE4 is related to these responses. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2. It prevents the activation of the MAPK/ERK pathway, potentially affecting proteins regulated by this pathway. This could result in decreased functional activity of V1RE4 if it is a downstream effector. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways. Inhibiting JNK can lead to changes in gene expression and apoptosis. If V1RE4 is regulated by JNK, this would lead to a reduction in V1RE4 activity. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a potent inhibitor of mTOR kinase, affecting both mTORC1 and mTORC2 complexes. The reduced mTOR signaling can impact the protein synthesis and survival pathways that might be required for the functional activity of V1RE4. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins, leading to cell cycle arrest and apoptosis. If V1RE4 turnover is regulated by the ubiquitin-proteasome pathway, this could indirectly decrease its functional levels. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It prevents EGFR from activating downstream signaling pathways, such as PI3K/AKT and MAPK/ERK. If V1RE4 is activated by these pathways, gefitinib would decrease its activity. | ||||||